GastroHep最新文献

{"title":"A ‘real-world’ retrospective multi-centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis","authors":"Victoria Tatiana Kronsten,&nbsp;Michael J. Colwill,&nbsp;Shadab Nayeemuddin,&nbsp;Jimmy K. Limdi,&nbsp;Christian Selinger,&nbsp;Glyn Scott,&nbsp;Lulia Al-Hillawi,&nbsp;Shayon Salehi,&nbsp;Paul Blaker,&nbsp;Guy Chung-Faye,&nbsp;Alexandra J. Kent,&nbsp;Patrick Dubois,&nbsp;Bu Hayee","doi":"10.1002/ygh2.467","DOIUrl":"https://doi.org/10.1002/ygh2.467","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Anti-tumour necrosis factor therapy is an established treatment for moderate-to-severely active ulcerative colitis (UC). Recent network meta-analyses of controlled trial data have indicated a superiority of intravenous drugs (infliximab) over subcutaneous (adalimumab). We conducted a retrospective multi-centre cohort study to determine the comparative effectiveness of these two drugs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patients with UC administered infliximab or adalimumab as their first biologic, identified from the therapy databases of five UK hospitals, were included, if they had completed induction and were on maintenance treatment. Patients receiving infliximab as ‘rescue’ therapy for acute severe UC were excluded. The primary end-points for comparison were the number of patients remaining on initial therapy (infliximab or adalimumab) at 52 weeks and the number of patients in clinical remission at 52 weeks (Simple Clinical Colitis Activity [SCCAI] score ≤ 3).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seventy-eight infliximab and 63 adalimumab patients were analysed. At 52 weeks, 83% of infliximab patients and 59% of adalimumab patients remained on therapy (<i>P</i> = 0.001). At 52 weeks, 62% of the infliximab group were in clinical remission compared to 32% of the adalimumab group (<i>P</i> = 0.0004). Primary non-response was reported in 24% of adalimumab patients and 5% of infliximab patients (<i>P</i> = 0.001). There were no significant differences in colectomy rates or hospital admission for acute flares at 52 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Our real-world results affirm the findings of network meta-analyses of clinical trials, suggesting that infliximab is superior to adalimumab in the maintenance of remission in UC up to 52 weeks.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 4","pages":"229-235"},"PeriodicalIF":0.0,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.467","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71936436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A ‘real‐world’ retrospective multi‐centre cohort study comparing infliximab and adalimumab for the maintenance of remission in ulcerative colitis","authors":"V. Kronsten, M. Colwill, S. Nayeemuddin, J. Limdi, C. Selinger, G. Scott, L. Al‐Hillawi, S. Salehi, P. Blaker, G. Chung-Faye, A. Kent, P. Dubois, B. Hayee","doi":"10.1002/ygh2.467","DOIUrl":"https://doi.org/10.1002/ygh2.467","url":null,"abstract":"Anti‐tumour necrosis factor therapy is an established treatment for moderate‐to‐severely active ulcerative colitis (UC). Recent network meta‐analyses of controlled trial data have indicated a superiority of intravenous drugs (infliximab) over subcutaneous (adalimumab). We conducted a retrospective multi‐centre cohort study to determine the comparative effectiveness of these two drugs.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"45 1","pages":"229 - 235"},"PeriodicalIF":0.0,"publicationDate":"2021-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73318319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral simethicone tablets with PEG‐ELS split‐prep reduces frequency of inadequate bowel cleansing and decreases bubbles","authors":"Jennifer K. Maratt, Alison E. Freeman, P. Schoenfeld, S. Saini, G. Su, A. Tai, A. Prabhu, J. Rubenstein, A. Waljee, Lisa Glass, D. Dang, N. Parikh, S. Govani, Swati G. Patel, Stacy B. Menees","doi":"10.1002/ygh2.469","DOIUrl":"https://doi.org/10.1002/ygh2.469","url":null,"abstract":"Intraluminal bubbles may prevent the visualisation of mucosa during a colonoscopy. Simethicone minimises bubbles, but its impact on incomplete bowel preparation and optimal protocols for use are unclear.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"159 1","pages":"254 - 260"},"PeriodicalIF":0.0,"publicationDate":"2021-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74116928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dried blood spot‐based detection of serological profiles of hepatitis B and C infections and their prevalence in Cambodia","authors":"Bunthen E, Ko Ko, Shintaro Nagashima, Serge Ouoba, Md Razeen Ashraf Hussain, Aya Sugiyama, T. Akita, Masayuki Ohisa, Channarena Chuon, B. Mao, M. Hossain, V. Ork, J. Tanaka","doi":"10.1002/ygh2.468","DOIUrl":"https://doi.org/10.1002/ygh2.468","url":null,"abstract":"This study aims to examine the diagnostic accuracy of dried blood spot (DBS) samples contrast to serum samples for detection of hepatitis B virus (HBV) and hepatitis C virus (HCV) sero‐markers in large scale epidemiological study in the resource limited settings and then to determine the prevalence of each sero‐marker from DBS samples collected during 2017 Cambodia nationwide study.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"100 1","pages":"247 - 253"},"PeriodicalIF":0.0,"publicationDate":"2021-05-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80308396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Addressing the long-term mortality risk in patients admitted with diverticulitis","authors":"Christopher Harmston","doi":"10.1002/ygh2.459","DOIUrl":"https://doi.org/10.1002/ygh2.459","url":null,"abstract":"Diverticular disease is extremely common in the western world, and the commonest emergency manifestation of diverticular disease is diverticulitis. This commonly presents to emergency physicians, with a high rate of acute hospital admissions and a need for emergency surgical intervention in some patients. The rate of diverticulitis is likely to be increasing, especially in a younger population, with a subsequent increase in the rates of hospitalisation. Despite this the rate of complicated diverticulitis has remained relatively static.1,2 These findings may be due to the increased use of computed tomography, but none the less, diverticulitis places significant financial and resource burden on most modern healthcare systems.3 Diverticulitis is known to be more common in patients with obesity, smokers and in males, its incidence can be reduced with a healthy diet and regular physical activity. The shortterm outcomes in cohorts of patients treated for diverticulitis are relatively well understood, but few comparative studies are available. As would be expected these shortterm outcomes are worse with increasing age, comorbidities and the need for acute surgical intervention. Longer term outcomes in patients following diverticulitis are less well understood and specifically the longterm impact on mortality of an admission with diverticulitis is poorly documented. The ability to assess diverticulitis as a marker of risk, and to properly council our patients on the implication of their disease is therefore compromised. In this issue of GastroHep, Granlund et al present a large, welldesigned study comparing both the shortand longterm mortality in patients admitted with diverticulitis with a diseasefree cohort.4 The authors present a 20year nationwide cohort study comparing outcomes in patients admitted with a firsttime diagnosis of diverticulitis with matched diseasefree individuals. ICD coding was used to identify patients. Information on covariates including education level, civil status and comorbidities was also collated and entered into a cox regression. The primary outcome event of interest was mortality, with time periods of within 100 days and from 101 days5 years used. Over 83 000 patients with diverticulitis were included and compared to over eight hundred thousand matched diseasefree individuals. Mortality within 100 days was four times higher than diseasefree individuals with a significantly higher rate in those undergoing surgical intervention. From day 1015 years hazard rates were increased by 11%, again with highest rates in patients undergoing operative intervention. The proportion of individuals who died within 100 days and within five years or admission was 4.1% and 20.3% in the diverticulitis cohort compared to 0.8% and 14.5% in diseasefree individuals. The study is well designed with high numbers of patients, however, as the authors acknowledge, in keeping with all studies of this type, classification and coding of diverticulitis was ","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 3","pages":"120"},"PeriodicalIF":0.0,"publicationDate":"2021-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.459","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71963912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of extrahepatic cancer in a nationwide cohort of hepatitis C virus infected persons treated with direct-acting antivirals","authors":"Charlotte Lybeck,&nbsp;Daniel Bruce,&nbsp;Scott M. Montgomery,&nbsp;Soo Aleman,&nbsp;Ann-Sofi Duberg","doi":"10.1002/ygh2.456","DOIUrl":"https://doi.org/10.1002/ygh2.456","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and aims</h3>\u0000 \u0000 <p>Direct-acting antivirals (DAAs) against HCV have an immune modulatory effect, this could possibly lead to a decreased tumour control. We, therefore, aimed to assess the risk of extrahepatic cancer (EHC) during and the first years after DAA treatment.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods and Results</h3>\u0000 \u0000 <p>This is a nationwide cohort study with prospectively collected data for 19 685 persons with HCV, 4013 DAA treated, 3071 interferon (IFN) treated and 12 601 untreated, from 2008 to 2016. Follow-up time was maximum 3 years. The risk for EHC was compared between the groups using Cox regression analyses, with adjustment for age and Charlson Comorbidity Index (CCI). The HCV-infected groups were also compared with matched cohorts without HCV from the general population. In total 341 EHCs were identified, 84, 43 and 214 EHC in the DAA, IFN and untreated group respectively. The EHC risk in DAA treated compared with IFN treated was doubled, but when adjusted for age and CCI the HR was 1.07 (95% CI 0.74-1.56). Compared with the general population, the HR of EHC for the DAA group was 1.45 (CI 1.13-1.86), with the difference remaining statistically significant after adjusting for CCI.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>We found no increased risk for EHC associated with DAA therapy after adjustment for age and CCI. An increased risk of EHC in DAA treated compared with the general population was though seen, and attention should be paid to this association in the ageing population with a history of HCV infection.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 3","pages":"185-195"},"PeriodicalIF":0.0,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.456","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71947528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver disease symptoms are associated with higher risk of adverse clinical outcomes: A longitudinal study of North American adults with chronic Hepatitis B","authors":"Donna M. Evon,&nbsp;Hsing-Hua S. Lin,&nbsp;Robert J. Fontana,&nbsp;Mandana Khalili,&nbsp;Colina Yim,&nbsp;Abdus S. Wahed,&nbsp;Jay H. Hoofnagle,&nbsp;the Hepatitis B Research Network (HBRN)","doi":"10.1002/ygh2.458","DOIUrl":"10.1002/ygh2.458","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Symptoms of chronic hepatitis B (CHB) are not well characterised.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>To evaluate CHB symptoms and associations with disease activity and clinical outcomes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Longitudinal data from 1576 participants in the Hepatitis B Research Network Cohort Study who completed symptom assessments were analysed. A composite symptom score was calculated using a Symptom Checklist (0 = none to 40 = extreme). Multivariable mixed models assessed variables associated with symptom change over time. Latent class symptom trajectories were evaluated. The cumulative probability of long-term clinical outcomes (new onset cirrhosis, hepatic decompensation, hepatocellular carcinoma, liver transplantation, death) was examined by baseline symptom groups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Participants median age was 42 (range: 18-80), 51% were male, 75% Asian, (68% of whom were born outside North America) with a median follow-up of 4.2 years. On average, symptoms did not significantly change over time. The multivariable model identified several variables associated with higher symptoms during follow-up: being female, non-Asian, born in the United States/Canada, lower education, higher AST, lower platelets and more comorbidities. Two patient subgroups were identified based on longitudinal symptom trajectories: a low symptom group (92%, n = 1451) with symptom scores averaging 2.4 over time and a moderate symptom group (8%, n = 125) with symptom scores averaging 11.5. During follow-up, 7.3% in the moderate symptom group, but only 3.2% of the low symptom group, developed adverse outcomes (<i>P</i> = 0.02).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this large cohort of CHB patients, symptoms were generally mild and stable over time. However, in some patients with moderate symptoms at baseline, deleterious clinical outcomes were more frequent at follow-up.</p>\u0000 \u0000 <p>ClinicalTrials.gov Identifier: NCT01263587.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 3","pages":"196-208"},"PeriodicalIF":0.0,"publicationDate":"2021-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.458","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39334062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic accuracy of patient-reported outcomes in predicting endoscopic subscore in patients with ulcerative colitis","authors":"Jean-Frederic Colombel,&nbsp;Peter L. Lakatos,&nbsp;Genoile O. Santana,&nbsp;Andrew G. Bushmakin,&nbsp;Joseph C. Cappelleri,&nbsp;Nervin Lawendy,&nbsp;Dario Ponce de Leon,&nbsp;Nicole Kulisek","doi":"10.1002/ygh2.457","DOIUrl":"https://doi.org/10.1002/ygh2.457","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). In patients with UC, associations between endoscopic findings and UC symptoms are not well described.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>Post hoc analysis of data from two randomised, placebo-controlled, 8-week, phase 3 studies of tofacitinib for the treatment of patients with UC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Associations of stool frequency and rectal bleeding subscores with endoscopic improvement (Mayo endoscopic subscore ≤1) were assessed and relationships studied using regression analyses.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Analysis of two-by-two contingency tables showed that dichotomised stool frequency and rectal bleeding were each or both not good predictors of endoscopic improvement. Using stool frequency and/or rectal bleeding as predictors of endoscopic subscore, regression modelling analyses demonstrated a weak relationship between variables. However, a robust relationship was observed with endoscopic subscore as a predictor of stool frequency and rectal bleeding. In OCTAVE Induction 1, normal/inactive disease (endoscopic subscore 0) corresponded to a least-squares mean value of 0.05 for rectal bleeding (no blood), and severe disease (endoscopic subscore 3) corresponded to a value of 1.5 (interpreted as streaks of blood with stool &lt;50% of the time [score of 1] or obvious blood with stool most of the time [score of 2]). OCTAVE Induction 2 results were similar.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Results suggest that the likelihood of endoscopic improvement or normalisation is higher in patients with normal stool frequency and without rectal bleeding, but that these symptoms alone are not predictive of endoscopic improvement or normalisation, and endoscopy is needed for disease assessment.</p>\u0000 \u0000 <p>ClinicalTrials.gov: NCT01465763; NCT01458951.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 3","pages":"161-168"},"PeriodicalIF":0.0,"publicationDate":"2021-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.457","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71944544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting mortality for cirrhotic patients with acute oesophageal variceal haemorrhage using liver‐specific scores","authors":"A. Z. Terres, R. Balbinot, A. L. Muscope, L. Eberhardt, J. I. Balensiefer, B. Cini, Gilberto L. Rost, M. L. Longen, B. Schena, R. A. Balbinot, S. Balbinot, J. Soldera","doi":"10.1002/ygh2.460","DOIUrl":"https://doi.org/10.1002/ygh2.460","url":null,"abstract":"Acute oesophageal variceal haemorrhage (AOVH) is one of the most common complications of cirrhosis, treated with terlipressin plus endoscopic variceal banding. Identifying patients with a high chance to survive is paramount in order to allocate resources with accuracy. The purpose of this study was to analyse if liver‐specific scores are capable of prognosticating mortality for AOVH patients.","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"111 4","pages":"236 - 246"},"PeriodicalIF":0.0,"publicationDate":"2021-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91472801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting mortality for cirrhotic patients with acute oesophageal variceal haemorrhage using liver-specific scores","authors":"Alana Z. Terres,&nbsp;Rafael S. Balbinot,&nbsp;Ana L. F. Muscope,&nbsp;Louise Z. Eberhardt,&nbsp;Juline I. L. Balensiefer,&nbsp;Bruna T. Cini,&nbsp;Gilberto L. Rost Jr.,&nbsp;Morgana L. Longen,&nbsp;Bruna Schena,&nbsp;Raul A. Balbinot,&nbsp;Silvana S. Balbinot,&nbsp;Jonathan Soldera","doi":"10.1002/ygh2.460","DOIUrl":"https://doi.org/10.1002/ygh2.460","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Acute oesophageal variceal haemorrhage (AOVH) is one of the most common complications of cirrhosis, treated with terlipressin plus endoscopic variceal banding. Identifying patients with a high chance to survive is paramount in order to allocate resources with accuracy. The purpose of this study was to analyse if liver-specific scores are capable of prognosticating mortality for AOVH patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design and setting</h3>\u0000 \u0000 <p>Historical cohort study was conducted in a public tertiary care teaching hospital.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from medical records from 2010 to 2016 were obtained by searching the hospital electronic database patients who received terlipressin. Charts were reviewed in order to determine the diagnosis of cirrhosis and AOVH. Data in these charts were reviewed and multiple variables were collected. The study included 97 patients. Liver-specific scores were calculated and ROC-curves pairwise comparisons were performed using DeLong test.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Model for End-Stage Liver Disease-Sodium (MELD-Na) was able to predict mortality in 30 and 90-day, with AUROC of 0.76 and 0.78 respectively. Values of MELD-Na above 17 were able to predict higher mortality for all patients, with the sensitivity of 69% and 67% and the specificity of 75% and 77% for 30 and 90-day mortality respectively (<i>P</i> &lt; 0.05). Although, when stratifying for acute-on-chronic liver failure patients, Chronic Liver-Failure-Sequential Organ Failure Assessment (CLIF-SOFA) performed better than other liver-specific scores, whereas Child-Turcotte-Pugh performed better for acute decompensation patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>MELD-Na score was superior to other liver-specific scores for predicting mortality in a cohort of cirrhotic patients admitted due to AOVH in a tertiary hospital.</p>\u0000 </section>\u0000 </div>","PeriodicalId":12480,"journal":{"name":"GastroHep","volume":"3 4","pages":"236-246"},"PeriodicalIF":0.0,"publicationDate":"2021-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/ygh2.460","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71944551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}